De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Genfit Beheer

Beheer criteriumcontroles 4/4

De CEO Genfit's is M. Prigent, benoemd in Sep2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt € 664.22K, bestaande uit 59.3% salaris en 40.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde € 143.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.3 jaar.

Belangrijke informatie

M. Prigent

Algemeen directeur

€664.2k

Totale compensatie

Percentage CEO-salaris	59.3%
Dienstverband CEO	5.1yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	7.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is M. Prigent's beloning veranderd ten opzichte van Genfit's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€22m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

Compensatie versus markt: De totale vergoeding ($USD 735.25K ) M. } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 763.35K ).

Compensatie versus inkomsten: De vergoeding van M. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

M. Prigent (55 yo)

5.1yrs

Tenure

€664,224

Compensatie

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.3yrs	€359.01k	0.094% € 223.2k
M. Prigent	Chief Executive Officer	5.1yrs	€664.22k	0.062% € 147.1k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Thomas Baetz	Chief Financial Officer	3.5yrs	geen gegevens	geen gegevens
Pascal Caisey	Chief Operating Officer	2.6yrs	geen gegevens	0.0095% € 22.6k
Meriam Kabbaj	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Dean Hum	Chief Scientific Officer	2.8yrs	€795.03k	0.021% € 49.3k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.6yrs	geen gegevens	0.0094% € 22.4k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.8yrs	geen gegevens	0.023% € 53.8k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.6yrs	geen gegevens	0.0055% € 13.2k
Emilie Desodt	Executive Vice President of Human Resources	2.6yrs	geen gegevens	0.0035% € 8.3k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.5yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0QT6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.3yrs	€359.01k	0.094% € 223.2k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Philippe Moons	Board Observer	3.7yrs	€7.63k	0.0021% € 5.0k
Florence Séjourné	Director	7.3yrs	geen gegevens	geen gegevens
Scott L. Friedman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Arun Sanyal	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Trauner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Catherine Larue	Independent Director	7.3yrs	€43.60k	geen gegevens
Vlad Ratziu	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anne-Helene Monsellato	Independent Director	7.3yrs	€39.24k	geen gegevens
Katherine Kalin	Independent Director	4.3yrs	€39.24k	0.010% € 24.0k
Eric Baclet	Independent Vice-Chairman of the Board	4.3yrs	€47.96k	0.0024% € 5.7k

7.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0QT6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).

Genfit Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Investor sentiment improves as stock rises 25%

First half 2024 earnings released: EPS: €0.61 (vs €0.42 loss in 1H 2023)

New major risk - Share price stability

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.16

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.78

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

New 90-day low: €3.09

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.60

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd